Vector Precision Driving the Future of In Vivo and Ex Vivo Gene Therapies

Vector precision is increasingly shaping the future of gene therapy, playing a critical role in both in vivo and ex vivo applications. This topic was explored in a recent interview featured by IBTV at Terrapinn’s Advanced Therapies London 2026.

During the interview, Natalia Elizalde, PhD, Chief Business Development Officer, highlighted why advances in lentiviral vector precision are essential for the next generation of gene therapies. Innovations such as cell‑specific targeting, tissue‑specific promoters, and immune evasion strategies are expected to be key to improving the effectiveness and success of in vivo lentiviral vector approaches.

At VIVEbiotech, this same precision mindset is applied across both in vivo and ex vivo lentiviral vector programs, supporting development from early research stages through to GMP manufacturing and commercialization. By combining deep vector expertise with scalable manufacturing capabilities, VIVEbiotech helps partners translate advanced science into impactful gene therapy solutions.

The full interview can be viewed in VIVEbiotech’s LinkedIn post, where the conversation and key insights shared during the event are available on video.

VIVEbiotech thanks IBTV for spotlighting this important discussion and contributing to the conversation around the future of gene therapy.